Showing 4411-4420 of 5771 results for "".
- Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-health-initiates-second-phase-3-study-for-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2478590/Bausch + Lomb announced the initiation of the second of two phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meib
- NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreementhttps://modernod.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/NovaBay Pharmaceuticals announced the signing of an agreement with Paragon Care Group Australia Pty for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021. “
- AstraZeneca Says COVID-19 Vaccine Candidate Shows 70% Efficacyhttps://modernod.com/news/astrazeneca-says-covid-19-vaccine-candidate-shows-70-efficacy/2478588/AstraZeneca announced that a combined interim analysis of late-stage studies showed that the COVID-19 candidate vaccine AZD1222 had an average efficacy of 70%, increasing to 90% for a regimen that included initial immunization with a half dose. The pooled data come from the COV002 phase 2/3 trial
- Tarsus Pharmaceuticals Appoints Wendy Yarno to Board of Directorshttps://modernod.com/news/tarsus-pharmaceuticals-appoints-wendy-yarno-to-board-of-directors/2478584/Tarsus Pharmaceuticals announced the appointment of Wendy L. Yarno to its Board of Directors and its audit committee. Ms. Yarno has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck &a
- HumanOptics Launches Triva Trifocal IOLhttps://modernod.com/news/humanoptics-launches-triva-trifocal-iol/2478583/HumanOptics announced the European launch of the Triva trifocal IOL for presbyopia correction. The Triva, which received CE Mark approval in February, provides excellent visual results with three focal points—n
- Eversight-Led Research Confirms Presence of SARS-CoV-2 in Postmortem Ocular Tissuehttps://modernod.com/news/eversight-led-research-confirms-presence-of-sars-cov-2-in-postmortem-ocular-tissue/2478578/Eversight announced research findings showing a small but noteworthy prevalence of SARS-CoV-2 in ocular tissues from individuals who died from COVID-19. The findings were presented Nov. 7 at the
- SIFI Completes Enrollment of the Phase 3 Study of Polihexanide 0.08% for the Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-completes-enrollment-of-the-phase-3-study-of-polihexanide-0-08-for-the-treatment-of-acanthamoeba-keratitis/2478575/SIFI announced that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its pivotal phase 3 clinical trial (043/SI). The full enrollment in the trial is an important milestone in addressing the unmet need for treating AK infections. It also paves the way
- Post-Treatment Application of Cryopreserved Amniotic Membrane (Prokera Slim) May Be Useful in Treating Infectious Corneal Ulcershttps://modernod.com/news/post-treatment-application-of-cryopreserved-amniotic-membrane-prokera-slim-may-be-useful-in-treating-infectious-corneal-ulcers/2478577/Bio-Tissue announced the results of a retrospective, case-control study,
- Pfizer, BioNTech’s COVID-19 Vaccine Shows 95% Efficacy Rate at Final Analysishttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-shows-95-efficacy-rate-at-final-analysis/2478571/Pfizer and BioNTech announced Wednesday that their mRNA-based COVID-19 vaccine candidate BNT162b2 demonstrated an efficacy rate of 95% at the final efficacy analysis of a phase 3 study. The companies noted the primary objective analysis is based on 170 cases of COVID-19, of which 162 cases were o
- Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelineshttps://modernod.com/news/hydrus-microstent-receives-highest-designation-of-any-migs-device-as-part-of-aao-treatment-guidelines/2478570/Ivantis, developer of the novel Hydrus Microstent MIGS device, announced that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation.” The designation is the highest of any MIGS device in its 2020 Preferred Practice Pa